Table 2

Adjusted ORs for complement factors measured at 12–15 and 16–19 weeks

Predictor variableBb (12–15 weeks)
n=323 subjects, 70 events
Bb (16–19 weeks)
n=317 subjects, 60 events
sC5b-9 (12–15 weeks)
n=320 subjects, 68 events
sC5b-9 (16–19 weeks)
n=317 subjects, 60 events
OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
Non-Hispanic white (yes vs no)0.74 (0.39 to 1.40)0.350.64 (0.32 to 1.27)0.200.70 (0.37 to 1.33)0.270.55 (0.28 to 1.09)0.086
SLE status (positive vs negative)1.27 (0.51 to 3.22)0.610.82 (0.31 to 2.18)0.691.07 (0.43 to 2.71)0.880.72 (0.27 to 1.95)0.52
LAC status (positive vs negative)5.81 (2.55 to 13.25)<0.0012.41 (0.94 to 6.15)0.0676.58 (2.89 to 14.98)<0.0012.85 (1.12 to 7.26)0.028
History of thrombosis (yes vs no)2.51 (1.11 to 5.65)0.0272.85 (1.26 to 6.46)0.0122.35 (1.04 to 5.29)0.0402.73 (1.23 to 6.08)0.014
Diastolic pressure>80 mm Hg
(yes vs no)
3.13 (1.42 to 6.91)0.0054.46 (2.01 to 9.88)<0.0012.82 (1.29 to 6.20)0.0104.27 (1.97 to 9.26)<0.001
Aspirin use (yes vs no)0.57 (0.29 to 1.11)0.0950.58 (0.28 to 1.17)0.130.57 (0.29 to 1.12)0.1040.65 (0.32 to 1.31)0.22
Current antihypertensive
(yes vs no)
3.82 (1.44 to 10.10)0.0074.37 (1.60 to 11.95)0.0044.61 (1.75 to 12.14)0.0024.37 (1.64 to 11.63)0.003
BMI0.430.480.270.18
 < 251111
 25–300.78 (0.38 to 1.59)0.82 (0.36 to 1.82)0.70 (0.34 to 1.45)0.68 (0.31 to 1.51)
 > 301.28 (0.54 to 3.02)1.33 (0.53 to 3.36)1.29 (0.55 to 3.05)1.42 (0.57 to 3.51)
Bb per SD increase*1.41 (1.06 to 1.89)0.0191.59 (1.16 to 2.17)0.004————
sC5b-9 per SD increase*————1.37 (1.05 to 1.80)0.0221.26 (0.94 to 1.68)0.12
Hosmer-Lemeshow
goodness-of-fit test
0.850.320.300.22
AUC0.800.800.800.80
Cross-validated AUC0.760.750.760.74
  • *SD for Bb=0.38 µg/mL at 12–15 weeks and 0.37 µg/mL at 16–19 weeks; SD for sC5b9=196 ng/mL at 12–15 weeks and 223 ng/mL at 16–19 weeks.

  • AUC, area under the ROC curve; BMI, body mass index; LAC, lupus anticoagulant; SLE, systemic lupus erythematosus.